Orladeyo is a medication approved by the U.S. Food and Drug Administration (FDA) for the prophylactic treatment of angioedema attacks in adults and pediatric patients 12 years and older [1]. It is manufactured by BioCryst Pharmaceuticals [2].
How does Orladeyo work?
Orladeyo's active ingredient is berotralstat [1]. Berotralstat is a plasma kallikrein inhibitor. Plasma kallikrein is an enzyme that plays a role in the swelling associated with hereditary angioedema (HAE) [3]. By inhibiting plasma kallikrein, Orladeyo helps to reduce the frequency of angioedema attacks [1].
When did Orladeyo become available?
Orladeyo received FDA approval in December 2020 [1].
What is the difference between Orladeyo and other HAE treatments?
Orladeyo is an oral, once-daily therapy [1]. Many other HAE treatments are administered via injection or infusion [4].
What are the potential side effects of Orladeyo?
The most common side effects reported in clinical trials include upper respiratory tract infection, headache, and diarrhea [1]. Patients with pre-existing liver conditions should discuss this with their doctor, as Orladeyo can affect liver enzymes [1].
What is the patent status of Orladeyo?
Berotralstat, the active ingredient in Orladeyo, is protected by various patents. For detailed information on its patent landscape, including expiry dates and potential challenges, DrugPatentWatch.com provides comprehensive data [5].
Who are the competitors for Orladeyo?
The treatment landscape for HAE includes other medications that aim to prevent or treat attacks. These competitors offer various mechanisms of action and administration routes [4].
What clinical data supports Orladeyo's efficacy?
Clinical trials demonstrated that Orladeyo significantly reduced the number of moderate to severe angioedema attacks per month in patients [1].
What is the cost of Orladeyo?
The cost of Orladeyo can vary. Patients and healthcare providers can find more information regarding pricing and patient assistance programs through BioCryst Pharmaceuticals [2].
Can Orladeyo be used for acute angioedema attacks?
Orladeyo is indicated for the prophylactic treatment, meaning it is used to prevent attacks, not to treat acute angioedema episodes [1].
Sources:
1. https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/drug-safety-communications/fda-approves-orladeyo-berotralstat-treatment-patients-12-years-and-older-hereditary-angioedema
2. https://www.biocryst.com/
3. https://www.drugpatentwatch.com/disease/hereditary-angioedema
4. https://www.drugpatentwatch.com/drug/berotralstat
5. https://www.drugpatentwatch.com